Oncología médica
Especialidad
Complejo Asistencial Universitario de Burgos
Burgos, EspañaPublicaciones en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (19)
2024
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328
2022
-
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
Oncotarget, Vol. 13, Núm. 1, pp. 812-827
-
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Lung Cancer, Vol. 173, pp. 83-93
2021
-
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
OncoTargets and Therapy, Vol. 14, pp. 5345-5352
-
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553
-
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists
Frontiers in Oncology, Vol. 11
2018
-
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
2017
-
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681
2016
-
147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
2015
2014
-
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer
Oncology Research, Vol. 21, Núm. 4, pp. 181-191
2013
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
-
Phase ii study of irinotecan in combination with capecitabine on a 3-weekly schedule as first-line chemotherapy for patients with metastatic or locally advanced colorectal cancer
Journal of Analytical Oncology, Vol. 2, Núm. 3, pp. 151-159
2012
-
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: A randomised phase II study
British Journal of Cancer, Vol. 107, Núm. 3, pp. 435-441
2006
-
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer
Anti-Cancer Drugs, Vol. 17, Núm. 1, pp. 89-94
2003
-
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil
Clinical Colorectal Cancer, Vol. 3, Núm. 3, pp. 174-179
-
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer
Lung Cancer, Vol. 39, Núm. 1, pp. 77-84